Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03325777 · ClinicalTrials.gov registry record · NA

Approach Bias Retraining to Augment Smoking Cessation

A NA study, sponsored by Jasper A. Smits.

Completed
Registry status
NA
Development phase
96
Enrollment target

NCT03325777: Completed NA study, sponsored by Jasper A. Smits.

NCT03325777 is a NA study that has completed, run by Jasper A. Smits. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03325777, a NA study, has completed, sponsored by Jasper A. Smits.

COMPLETED
Registry status
NA
Development phase
96 participants
Enrollment target

Study Summary

Tobacco use is the most preventable cause of disease, disability, and death in the United States. Standard smoking cessation care (cognitive behavioral therapy and nicotine replacement therapy), is effective in approximately 20% of the cases, clearly indicating there is substantial room for improvement. Current work suggests that despite standard interventions, continued substance abuse may result from addictive behaviors governed partly through automatic processes that exert their influence outside conscious control. This is important from a treatment perspective, as we should develop treatments to target implicit processes. Among a number of promising targets for intervention, cognitive biases are important to address as they have been implicated as maintenance factors for addiction. Approach bias, defined as the automatically activated action tendency to approach smoking-related stimuli, is a relatively novel cognitive bias and has been related to failed smoking cessation. A recently developed task for approach bias assessment is the Approach Bias Retraining (ABR), a computerized joystick task increasingly used to measure automatic approach tendencies in addiction research. This clinical trial will evaluate a smoking cessation intervention that integrates standard care with approach bias retraining. Results will provide novel information regarding the potential benefits of engaging implicit cognitive biases as a means to augment traditional smoking cessation therapy. This study has the potential to help individuals attempting to quit smoking and, ultimately, provide unique information about the importance of targeting implicit processes to complement standard care.

Primary Outcome

The primary outcomes were 7-day point-prevalence abstinence (PPA) and prolonged abstinence (PA) at 3-month follow-up (week 18). PPA was defined as self-report of no smoking (not even a puff) during the previous 7 days. Failure to maintain PA at any assessment was defined as smoking on 7 consecutive days or smoking at least once each week over the last 2 consecutive weeks. PPA and PA were assessed by study staff at each appointment using sequential timeline follow-back interviews and biochemical

Interventions

  • BEHAVIORAL Approach Bias Retraining
  • BEHAVIORAL SHAM Training

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2017-11-29
Est. Completion 2021-10-08
Phase NA
Jasper A. Smits

8 total trials

What the finished NCT03325777 record still lists

NCT03325777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Approach Bias Retraining is the first listed.

NCT03325777 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03325777 about?

NCT03325777 is a clinical study titled "Approach Bias Retraining to Augment Smoking Cessation". Tobacco use is the most preventable cause of disease, disability, and death in the United States. Standard smoking cessation care (cognitive behavioral therapy and nicotine replacement therapy), is effective in approximately 20% of the cases, clearly indicating there is substantial room for improvem...

What is the current status of trial NCT03325777?

This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2017-11-29. Estimated completion is 2021-10-08.

What interventions are being tested in trial NCT03325777?

The interventions under investigation include: Approach Bias Retraining (BEHAVIORAL), SHAM Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT03325777?

This trial is sponsored by Jasper A. Smits, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03325777's enrollment target sits among peer trials

96 925th of 2000 higher than 1,070 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03325777, the US trial registry maintained by the National Library of Medicine. NCT03325777 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.